Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New therapy aims to ease trauma in ovarian cancer patients

NCT ID NCT07286162

Symptom relief Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase III trial tests a therapy called CALM-TF for women with advanced ovarian cancer who experience traumatic stress. 300 participants will either receive 3-6 sessions of this trauma-focused therapy or standard care. Researchers will measure stress, depression, and quality of life over 6 months to see if the therapy helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Trauma-Focused Managing Cancer and Living Meaningfully (CALM-TF) psychotherapy
What this could lead to
If it works, this could provide an effective therapy to reduce traumatic stress and improve quality of life for women with advanced ovarian cancer.
What could go wrong
This is a behavioral intervention, not a drug, so effects may be modest. The trial is not yet recruiting, and results depend on patient engagement and therapist skill.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed stage III or IV ovarian cancer OR recurrent ovarian cancer within six months of diagnosis or recurrence * Age 18 years or older * Able to speak and read English * Able to provide informed consent Exclusion Criteria: * Significant cognitive impairment that would interfere with the ability to participate in psychotherapy or complete study questionnaires * Active psychosis or severe psychiatric condition requiring immediate psychiatric intervention * Receiving ongoing psychotherapy at the time of recruitment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer (OVCA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer (OVCA) Recurrent ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.